Louis Moore Bacon's BRVE Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 78,715 shares of Braveheart Bio, Inc. (BRVE) worth $1.59 M, representing 0.03% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in BRVE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Braveheart Bio (BRVE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Braveheart Bio (BRVE) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +78,715 | New Buy | 78,715 | $20.20 |
Louis Moore Bacon's Braveheart Bio Investment FAQs
Louis Moore Bacon first purchased Braveheart Bio, Inc. (BRVE) in Q3 2026, acquiring 78,715 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Braveheart Bio, Inc. (BRVE) for 1 quarters since Q3 2026.
Louis Moore Bacon's largest addition to Braveheart Bio, Inc. (BRVE) was in Q3 2026, adding 78,715 shares worth $1.59 M.
According to the latest 13F filing for Q3 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 78,715 shares of Braveheart Bio, Inc. (BRVE), valued at approximately $1.59 M.
As of the Q3 2026 filing, Braveheart Bio, Inc. (BRVE) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Braveheart Bio, Inc. (BRVE) was 78,715 shares, as reported at the end of Q3 2026.